Related Experiment Video

Updated: Jun 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

[Mechanism and problem of amifostine in treating myelodysplastic syndromes]

Yan-Hui Dang1, Wei Li, Bo Yang

  • 1Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing 100853, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|December 25, 2009
PubMed

Insights

Myelodysplastic syndrome (MDS), a bone marrow disorder, affects elders but is increasingly seen in younger patients. This review explores amifostine

Area of Science:

  • Hematological Malignancies
  • Stem Cell Biology
  • Oncology

Context:

  • Myelodysplastic syndrome (MDS) is a prevalent hematological malignancy affecting elderly individuals, characterized by ineffective bone marrow hematopoiesis and peripheral blood cytopenias.
  • Risk factors for MDS include chemotherapy, radiotherapy, benzene exposure, and immunosuppressants, with concerning trends of increasing incidence and younger patient age.
  • Despite advancements in cancer therapeutics, current MDS treatments have limited efficacy, highlighting the need for novel therapeutic strategies.

Purpose:

  • To review the therapeutic mechanisms of amifostine in treating myelodysplastic syndrome (MDS).
  • To explore the challenges and current understanding of amifostine's role in MDS therapy.
  • To synthesize existing research on amifostine's potential as a pancytoprotective agent in MDS.

Summary:

  • Amifostine, a known pancytoprotector, is being investigated for its efficacy in managing myelodysplastic syndrome (MDS).
  • This review examines the underlying mechanisms by which amifostine may exert therapeutic effects in MDS.
  • The current understanding of amifostine's application in MDS is discussed in the context of ongoing scientific investigations.

Impact:

  • Provides insights into a potential therapeutic agent for myelodysplastic syndrome (MDS).
  • Highlights the need for further research into amifostine's mechanism of action and clinical utility in MDS.
  • Contributes to the scientific understanding of managing hematological malignancies with protective agents.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...